Correlation of SOCS‑1 gene with onset and prognosis of breast cancer

Abstract

The aim of the present study is to study the expressions of suppressor of cytokine signaling (SOCS)-1 in the tumor tissues and adjacent normal tissues of patients with breast cancer. The study was also planned to investigate the association of SOCS-1 gene expression with patients' clinical pathology, molecular subtype and prognosis. A total of 60 cases of frozen and paraffin-embedded specimens of tumor tissues and corresponding adjacent normal tissues of patients with breast cancer were selected. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was used to detect the expression levels of SOCS-1 messenger RNA (mRNA) in the patients' tumor tissues and adjacent normal tissues. The immunohistochemical method was applied to detect the expressions of SOCS-1 proteins in the patients' breast cancer tissues and adjacent normal tissues. Moreover, the correlations of SOCS-1 protein expressions in breast cancer tissues with patients' pathological parameters, molecular subtypes and prognosis were analyzed in combination with the clinical data. The results of RT-qPCR showed that the SOCS-1 mRNA expression in breast cancer tissues was significantly lower than that in adjacent normal tissues (p<0.01). The immunohistochemical results indicated that the positive expression rate of the SOCS-1 proteins in breast cancer tissues (23.33%) was remarkably lower than that in adjacent normal tissues (88.33%) (p<0.01). The low expression of SOCS-1 in breast cancer tissues was related to lymph node metastasis and clinical staging. The positive expression rates of the luminal A SOCS-1 proteins were the highest (47.62%) (p<0.01). The 5-year overall survival rate of the breast cancer patients was 63.33% (38/60). The univariate survival analysis revealed that the patients with low expression of SOCS-1 had poorer prognosis. In conclusion, the low expression of SOCS-1 plays a key role in the pathogenesis of breast cancer; in particular, it is associated with the lymph node metastasis and clinical staging of the tumor; so, the SOCS-1 expression in breast cancer tissues can be regarded as an important reference for the prognostic estimation of breast cancer.

Ecotropic virus integration‑1 and calreticulin as novel prognostic markers in triple‑negative breast cancer: A retrospective cohort study

“…1, which represents the difference of IOD among the different groups. The staining intensity was characterized as 0 points for no coloring, 1 point for weak staining, 2 points for medium staining and 3 points for strong staining (19,35,36). The percentage of positive cells was categorized as follows: 0 points for no positive cells, 1 point for ≤25% positive area, 2 points for 26–50% positive area, 3 points for 51–75% positive area and 4 points for >75% positive area.…”

Role of the JAK/STAT Pathway in Cervical Cancer: Its Relationship with HPV E6/E7 Oncoproteins

“…SOCS is a large family of proteins that negatively regulate JAK/STAT signaling. In cancer of the liver, lung, prostate, ovary, and breast, among others, there are antecedents that the reduction or silencing of one or more SOCS correlates with tumor progression and poor overall survival [ 155 , 156 , 157 , 158 , 159 ]. In cervical cancer, HPV can modulate the expression of different SOCS.…”

Comprehensive analysis of suppressor of cytokine signaling proteins in human breast Cancer

“…The suppressor of cytokine signaling (SOCS) family is a family of immunosuppressive proteins that was recently discovered and contains 8 members, including cytokine-inducible SH2-containing protein (CIS) and SOCS 1–7 proteins [ 6 , 7 ]. Since cytokine signaling plays an essential role in the initiation and development of human cancer, various studies have focused on elucidating the relationships between the expression of SOCS family members and different cancer types [ 8 , 9 ].…”

“…Using fresh frozen breast cancer tissue samples ( n = 127) and normal breast tissues ( n = 31), Sasi et al evaluated the expression levels of SOCS 1–7, and found higher mRNA expression levels of SOCS1, 3, 4, and 7 were significantly associated with early-stage tumor and more favorable prognosis in human breast cancer patients [ 13 ]. A recent study suggested that SOCS1 expression was low in breast cancer tissues and its expression level was associated with different clinical stages of breast cancer [ 6 ]. However, the distinctive roles of SOCS family proteins in breast cancer and the underlying mechanisms by which they are derepressed or activated have not been fully elucidated.…”